Omnicyte
New York, US · 1 known investors
OmniCyte is a biotechnology company developing vaccines and cancer immunotherapies, including a SARS-CoV-2 vaccine program and immune-response engineering work conducted in collaboration with academic medical centers. Its research focuses on recombinant vaccine development and immuno-oncology approaches.
Founders & leadership
PL
Peter LeonardiFounder and CEO
AP
Angel PellicerFounder and Investigator
Investors · 1
Competitors · 7
by search overlapIncyte Corporation9 shared keywordsIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
Celcuity8 shared keywordsCelcuity is a commercial-stage biotechnology company developing targeted cancer therapies for tumors involving the PAM (PI3K/AKT/mTOR) pathway, including breast, prostate, lung, endometrial, colon, and ovarian cancers. Its lead candidate, gedatolisib, targets all Class I PI3K isoforms and the mTORC1 and mTORC2 complexes and is being evaluated across multiple oncology clinical programs.
Rarecyte8 shared keywords
Kite Pharma6 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Kiniciti5 shared keywordsKiniciti is a platform company that operates cell and gene therapy-focused life science businesses, including Cellistic for iPSC-based manufacturing technologies and Ncardia for human iPSC products and drug discovery services. The company serves therapeutic developers and pharmaceutical companies seeking scalable cell therapy manufacturing and drug discovery solutions.
Lixte Biotechnology Holdings4 shared keywordsLixte develops cancer therapies, focusing on precision oncology and clinical drug development. The company works on advancing innovative treatments in the oncology field.
Oncotelic Therapeutics4 shared keywordsOncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
Companies competing with Omnicyte for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2021 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $199.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Omnicyte do?
- OmniCyte is a biotechnology company developing vaccines and cancer immunotherapies, including a SARS-CoV-2 vaccine program and immune-response engineering work conducted in collaboration with academic medical centers. Its research focuses on recombinant vaccine development and immuno-oncology approaches.
- Who founded Omnicyte?
- Omnicyte was founded by Peter Leonardi, Angel Pellicer.
- Who are Omnicyte's investors?
- Omnicyte's investors include Connecticut Innovations.
- Where is Omnicyte headquartered?
- Omnicyte is headquartered in New York, US.